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OBJECTIVE: The aim of this study was to evaluate the effect of oral tamoxifen treatment on the number of
myofibroblasts present during the healing process after experimental bile duct injury.
METHODS: The sample consisted of 16 pigs that were divided into two groups (the control and study groups).
Incisions and suturing of the bile ducts were performed in the two groups. Tamoxifen (20 mg/day) was
administered only to the study group. The animals were sacrificed after 30 days. Quantification of
myofibroblasts in the biliary ducts was made through immunohistochemistry analysis using anti-alpha smooth
muscle actin of the smooth muscle antibody. Immunohistochemical quantification was performed using a
digital image system.
RESULTS: In the animals treated with tamoxifen (20 mg/day), there was a significant reduction in
immunostaining for alpha smooth muscle actin compared with the control group (0.1155 vs. 0.2021, p=0.046).
CONCLUSION: Tamoxifen reduced the expression of alpha smooth muscle actin in the healing tissue after bile
duct injury, suggesting a decrease in myofibroblasts in the scarred area of the pig biliary tract. These data
suggest that tamoxifen could be used in the prevention of biliary tract stenosis after bile duct surgeries.
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& INTRODUCTION
Cholecystectomy is one of the most commonly performed
general surgery procedures in the world (1). With the advent of
video laparoscopy, nearly 90% of all cholecystectomies are
currently performed laparoscopically, which has resulted in an
increased incidence of bile duct injuries (BDIs). The incidence
has increased from 0.1-0.2% (open cholecystectomy) to 0.4-0.6%
(video laparoscopy) (2,3). Despite their low prevalence,
iatrogenic BDIs are significant with regard to their absolute
numbers (4) and are important in terms of health care costs (5,6);
furthermore, they are among the leading causes of negligence
claims against surgeons (7-10).
When the bile duct has lost continuity after injury from
cholecystectomy or other biliary operations, surgical recon-
struction is the only feasible treatment option (11,12).
Nevertheless, the management of major BDIs is a surgical
challenge (13), even for experienced hepatobiliary surgeons.
Due to the small caliber of the main bile duct, anastomosis is
difficult to perform and favors the occurrence of stenosis,
which is usually secondary to the inflammatory process and
fibrosis (14). The prevalence of bile duct stenosis varies from
0.2-0.5% (4) and can potentially progress to cholangitis,
biliary cirrhosis, portal hypertension, end-stage liver disease
and death (15,16).
Myofibroblast differentiation and activation are critical
events in the pathogenesis of human fibrotic diseases (17),
as is post-operative biliary stenosis. Myofibroblasts are
present in large numbers and represent the main cause of
scar contracture and the occurrence of fibrosis (18,19). These
cells exhibit features that are intermediate between fibro-
blasts and smooth muscle cells; specifically, they produce
collagen, they express alpha smooth muscle actin (a-SMA)
and their differentiation and activation are induced by
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transforming growth factor-beta 1 (TGF-b1) (17). Studies
have indicated that the expression of TGF-b1 in stenotic bile
ducts is significantly higher than that in normal bile ducts,
suggesting that TGF-b1 is a key factor in the prolonged
healing process of the bile duct and in the proliferation of
cicatrix (20,21).
Tamoxifen is a synthetic nonsteroidal antiestrogen agent
that exhibits antifibrotic properties and has been shown to
successfully treat many fibrotic diseases (e.g., hypertrophic
scars (22), keloids (22), encapsulating peritoneal sclerosis (23),
retroperitoneal fibrosis (24), fibrosing mediastinitis (25),
sclerosing cervicitis (25) and recurrent desmoid tumors
(26,27)). It is believed that the antifibrotic property of
tamoxifen is mainly due to its downregulation of TGF-b1
(22,28).
Considering that tamoxifen may inhibit the increase in
myofibroblasts during wound healing, the aim of this study
was to experimentally investigate the effect of oral tamox-
ifen treatment on the number of myofibroblasts in the
healing tissue after BDI.
& MATERIALS AND METHODS
This study was conducted with approval from the Ethics
Committee in Animal Experimentation of Fluminense
Federal University, Rio de Janeiro, Brazil.
Animals
Female pigs (Sus scrofa domesticus) of the LargeWhite breed
that weighed between 20 and 32 kg were used in the
experiments. The animals were kept under standard condi-
tions (12 h/12 h day/night cycle), were fed a standard diet
and received water ad libitum. For the sample size calculation,
a pilot study was carried out in which tamoxifen was
administered to three of the six animals. Considering an
effect size of 0.65, a significance level of 5% (a) and a statistical
test power of 80% (1-b), it was estimated that a minimum
sample size of nine animals would be needed for each
experimental group.
Eighteen pigs were included in this study and divided
into two groups: a control group without treatment (Group
A) and an experimental group treated with oral tamoxifen
(Group B).
Anesthesia and analgesia
The pigs were intramuscularly (IM) pre-medicated with
ketamine (5 mg/kg), midazolam (0.5 mg/kg) and aceproma-
zine (0.05 mg/kg). Anesthesia was induced with propofol
(4 mg/kg). After orotracheal intubation, an epidural blockwas
performed with bupivacaine 0.125% (10 mL) and morphine
(0.1 mg/kg). The isoflurane concentration was maintained at
1.5%. Tramadol was administered at a dose of 2 mg/kg to the
animals that exhibited pain during the post-operative period
and required rescue analgesic. Oxytetracycline (15 mg/kg IM)
was administered before and 48 hours after each surgery.
Surgical procedures
The peritoneal cavity was accessed using a right subcostal
incision. Dissection, ligation and sectioning of the cystic
artery, together with the cystic duct, were performed. The
gallbladder was dissected and removed. The hepatoduode-
nal ligament was opened and the bile duct was measured
using digital calipers from a location that was 1.5 cm away
from the superior border of the first portion of the
duodenum. In all of the animals, two repair stitches were
placed (on each side of the future incision) using 6.0
polypropylene sutures (Figure 1). A longitudinal 5-mm
incision was made in the anterior wall of the bile duct. This
incision was measured using digital calipers, starting from a
distance of 1 cm from the superior border of the first portion
of the duodenum and extending in the cranial direction
(Figure 2). These wounds were closed using four non-
continuous stitches that were distributed in an equidistant
manner and placed using 6.0 polydioxanone sutures
(Figure 3). To close the abdominal cavity, the musculoapo-
neurotic layer was sutured using simple running stitches of
2.0 vicryl sutures. The skin was closed using continuous,
simple running 3.0 nylon sutures.
Tamoxifen administration
Following the surgery, the group B animals received
tamoxifen at a dose of 20 mg/day orally for 30 days.
Data sampling
The animals were euthanized 30 days after the surgery.
After withholding food overnight, the animals were sedated
intramuscularly with ketamine (5.0 mg/kg), xylazine
(1.0 mg/kg) and acepromazine (0.1 mg/kg). Thiopental
sodium (5%) was administered intravenously to induce
anesthesia. When an animal was deeply anesthetized,
Figure 1 - Repair stiches in the choledoco duct.
Figure 2 - Longitudinal incision made in the anterior wall of the
biliary duct.
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potassium chloride (10%) was administered intravenously to
stop the heartbeat.
The bile duct from each animal was resected through a
median abdominal incision. The resected bile ducts were
opened longitudinally along the posterior wall and immersed
in 10% buffered formalin. The tissues were routinely
processed. Five-micron-thick sections were cut from paraffin
blocks, stained with hematoxylin and eosin and submitted for
immunohistochemistry analysis.
Immunohistochemical staining
After dewaxing, the presence of a-SMA protein was
assessed using immunohistochemistry by employing the
polymer method (Mach 4, Biocare Medical, Concord, CA,
USA). Endogenous peroxidase activity was blocked by
incubation in 1.3% H2O2 in methanol at room temperature
for 15 min. Antigen retrieval was performed by incubating
samples in Trilogy Antigen Retrieval Solution (Cell Mark,
Hot Springs, CA, USA) at 96 C˚ for 40 min. Non-specific
protein binding was blocked by incubation with Dako
Blocking Solution (Dako, Carpinteria, CA, USA) for 15 min
at 37 C˚. The sections were incubated for 1 hour at room
temperature with a 1:200 dilution of the primary monoclonal
antibody anti-a-SMA (clone 1A4, Cell Mark, Hot Springs, CA,
USA). Visualization was performed by incubation in diami-
nobenzidine for 5 min. The sections were counterstained
with Harris hematoxylin for 30 seconds. Between each step,
the sections were washed in phosphate-buffered saline (PBS
buffer). All of the incubations were carried out in humidified
chambers to prevent evaporation. Histological sections from
the uterus were used as a positive control. The negative
control was performed by omitting the primary antibody.
Image analysis
The immunohistochemical quantification of alpha smooth
muscle actin was performed using a digital image system
(Aperio Technologies, Vista, CA, USA). All of the glass
slides were scanned at an objective magnification of 40x
using a ScanScope
TM
CS scanning system (Aperio
Technologies, Vista, CA, USA). The positivity index (PI;
positive area/total area) was calculated for each image
within the scar area using the positive pixel count algorithm
in the ImageScope
TM
software (Aperio Technologies, Vista,
CA, USA). The pen tool was used to select the scar areas and
to exclude the immunopositive vessels.
Statistics
Statistical analysis was performed using the software SASH
System, version 6.11 (SAS Institute, USA). The results were
expressed as the median and interquartile intervals (Q1 and
Q3). The Shapiro-Wilk test was employed to examine the
normality of the data distribution. Comparisons of the PI and
surgical data between the two groups (control and study)
were performed using the Mann-Whitney test. The level of
significance was set at 5%.
& RESULTS
One animal from the control group died on the sixth day
after surgery from a biliary fistula and was excluded from
the study. Another pig was excluded from the experimental
group due to its characterization as an outlier, it once had
considerably higher PI value than did the other pigs: in the
interval between Q3+1.5*AIQ and Q3+3*AIQ; Q1 and Q3 are
the 1st and 3rd quartiles and AIQ corresponds to the
interquartilic amplitude (Q3-Q1). Therefore, the results were
analyzed and presented based on a total of 16 animals (eight
in each group). One representative immunohistochemical
image for alpha smooth muscle actin is shown in Figure 4.
Table 1 provides the surgical data of the control and study
groups. There were no statistically significant differences in
any of the parameters evaluated (p.0.05), demonstrating
the homogeneity of the groups according to the analyzed
parameters. Table 2 shows the descriptive data for the PI
values of the control and study groups and the correspond-
ing p values (Mann-Whitney test). The data are expressed as
the median and interquartile intervals (Q1-Q3). The study
group exhibited a significantly lower PI than the control
group (p= 0.046), as illustrated in Figure 5.
& DISCUSSION
This study investigated the effect of oral tamoxifen on the
myofibroblast count in the healing tissue after BDI in an
experimental pig model. To our knowledge, this is the first
study to investigate the possible use of oral tamoxifen as a
therapeutic option for reducing stenosis after bile duct
reconstruction. We observed that the oral treatment of pigs
with tamoxifen reduced the a-SMA expression in the healing
tissue after BDI, suggesting a reduction of the number of
myofibroblasts through the inhibition of TGF-b1 production.
Because the biliary tracts of pigs are anatomically similar
to those of humans, pigs have been used in many studies to
evaluate biliary tract processes (29-32). Therefore, the results
obtained in this study approximate the results that can be
expected in humans (9) because the greater the physiologi-
cal and anatomical similarity, the more applicable the
conclusions (33). The arterial supply of the common hepatic
duct and the bile duct have a longitudinal anastomotic chain
arranged in a ladder form in humans (34). Therefore, we
performed a longitudinal incision to maintain the best blood
supply in the scarring area.
Myofibroblasts are the principle cause of biliary tract
stenosis (35). In BDIs, the exposure of the underlying stroma
to bile appears to serve as a nidus for the crystallization of
biliary sludge and a stimulus for inflammation and the
Figure 3 - Biliary duct wound closing using separate stitches.
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activation of myofibroblasts (19). This process may lead to
biliary strictures due to wound contraction and fibrosis (19).
In addition to a-SMA, myofibroblasts also express smooth
muscle myosin isoforms, which are responsible for the
contraction and/or motility of smooth muscle (36).
Myofibroblasts also produce matrix proteins and additional
growth factors in response to proinflammatory cytokines
(36). After repair or scar formation, myofibroblasts are
eliminated by apoptosis (36). In dogs, myofibroblasts appear
one week after BDI, peak after three weeks and remain for a
long period (35). Therefore, we chose to sacrifice the animals
30 days after the surgery to ensure that the peak number of
myofibroblasts had been achieved.
In this study, myofibroblasts were identified using
immunohistochemistry with an anti-a-SMA antibody. It is
important to note that we used computerized digital image
analysis procedures to calculate the immunopositive areas.
Many studies use conventional pathologist-based manual
scoring of the immunohistochemical results (37-39), but this
approach suffers from a greater risk of interobserver and
intraobserver variability (40).
In a model of nephropathy in rats, tamoxifen exhibited an
antifibrotic effect that, according to the authors, could be
explained by its ability to reduce myofibroblast prolifera-
tion, as there was also a reduction of a-SMA expression (41).
In another study, tamoxifen inhibited keloid fibroblast
Table 1 - Surgical data for the control and study groups.
Variable Group Median Q1 Q3 p-value a
Weight at surgery (kg) control 26.5 25.0 28.7 0.83
study 27.0 24.8 30.3
Weight at necropsy (kg) control 33.3 31.0 36.8 0.71
study 33.3 27.8 35.0
Caliber of the bile duct at surgery (mm) control 7.31 6.07 10.43 0.79
study 7.53 6.99 8.15
Caliber of the bile duct at necropsy (mm) control 5.59 5.30 6.65 0.17
study 5.01 3.67 5.96
Duration of the surgery (min) control 55.0 46.0 71.0 0.95
study 58.5 54.5 65.0
Q1: 1st quartile; Q3: 3rd quartile, a Mann-Whitney test.
Figure 4 - Example of the immunostaining quantification using the digital imaging system (Aperio Technologies; USA). A. Tissue section
showing the scar area marked with a pen. B. Scar area showing immunopositivity for alpha smooth muscle actin. Blood vessels were
manually excluded using the pen tool. C. Results of the analysis: blue=no staining, yellow= low-intensity staining, orange=medium-
intensity staining and red=high-intensity staining.
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proliferation and decreased collagen production by decreas-
ing the expression of TGF-b1 (42). It is known that biliary
epithelial cells and periductal myofibroblasts are closed
linked because damage to the former leads to activation and
proliferation of the latter (19). Various experimental models
in rats have previously shown that estrogen plays a key role
in the biology of cholangiocytes (43,44) because the
administration of tamoxifen or ovariectomy reduces biliary
tree growth and induces cholangiocytes apoptosis (45,46).
This concept is consistent with the findings in humans that
estrogen receptors are over-expressed in the cholangiocytes
of primary biliary cirrhosis patients (47).
The present results should be interpreted in light of the
potential limitations of the study. First, it is not possible to
know whether the modulatory effect of tamoxifen would be
present in male animals because we only examined females.
However, this deliberate choice provided us with a more
homogeneous sample and enhanced the translational
impact of the results, considering that there is a known
higher prevalence of biliary gallstone disease in women.
Second, because we addressed the biliary wound healing
process after mechanical injury at a single one-month
follow-up time point, it is not known whether tamoxifen
exerts a long-lasting action. Further studies are needed to
describe the time course of this modulatory action of
tamoxifen. The one-month time point was chosen because
myofibroblast proliferation reaches its peak after three
weeks (35). Third, because our aim was specifically to
investigate the number of myofibroblasts present during the
biliary wound healing process, we did not obtain an
overview of the entire wound healing process, including
the changes in collagen. Although a more comprehensive
approach would be desirable, the present results are
straightforward and provide novel evidence for the mod-
ulatory role of tamoxifen in myofibroblast proliferation in
biliary wound healing.
Biliary duct reconstruction is complex and although a
large variety of suggested reconstruction techniques and
materials exist in the literature, the BDI treatment results are
still not satisfactory [49]. Therefore, other options must be
investigated to improve reconstruction outcomes. In con-
clusion, our results demonstrate that oral tamoxifen is a
promising therapeutic option for reducing stenosis after bile
duct reconstruction because it reduces the number of
myofibroblasts present in the healing tissue. More studies
must be undertaken to validate the inclusion of oral
tamoxifen in clinical practice.
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